Research to Watch: Lurbinectedin-Atezolizumab Combination Demonstrates Significant OS, PFS Benefits – ILCN.org (ILCN/WCLC)
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC.
Related Articles
Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers
Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.
Using Biopsies to Inform Response Characteristics in Kidney Cancer
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
CDK4/6 Inhibitors, Targeted Therapies May Expand Their Reach in HR+ Metastatic Breast Cancer
Hope S. Rugo, MD, discusses questions regarding CDK4/6 inhibitors and targeted therapies in HR-positive, HER2-negative advanced breast cancer.
Comment on “Stereotactic radiosurgery for patients with spinal metastases from prostate cancer”
Journal of Neuro-Oncology –
Daratumab Added to Standard Frontline AL Amyloidosis Treatment Demonstrates Improved Clinical Outcomes
In the final analysis of the ANDROMEDA study, additional daratumab to standard bortezomib, cyclophosphamide, and dexamethasone therapy demonstrated better hematological responses and clinical improvement for…
A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 1
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach
Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment.
Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials | JCO Oncology Practice
PURPOSEThis study aimed to determine complete toxicity reporting (CTR), and the use of subjective toxicity-minimizing language (TML) among phase III oncology trials.METHODSTwo-arm superiority-design phase III…
Leading the Way: Approaches in Biomarker Testing for HRD, Importance of Pilot Efforts – GynCancerCare OncLive
Discuss the importance of starting with pilot efforts to address challenges. Negotiate responsibilities across your team – reassess and reassign responsibilities based on expertise, availability,…